Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Antimicrobial Agents and Chemotherapy|February 5, 2020
Fosamprenavir with Ritonavir Pharmacokinetics during PregnancyAhizechukwu C Eke, Jiajia Wang, Khadija Amin, et al.
Antimicrobial Agents and Chemotherapy|September 30, 2010
Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1David Croteau, Scott Letendre, Brookie M Best, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2012
Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentrationDavid Croteau, Steven S Rossi, Brookie M Best, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2012
Therapeutic amprenavir concentrations in cerebrospinal fluidDavid Croteau, Scott Letendre, Brookie M Best, et al.
BMJ Open|November 27, 2020
Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trialSharana Mahomed, Nigel Garrett, Quarraisha A Karim, et al.
BMJ Open|August 28, 2023
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trialSharana Mahomed, Nigel Garrett, Disebo Potloane, et al.
The Journal of Infectious Diseases|June 5, 2024
Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032Kristina M Brooks, Kristin Baltrusaitis, Diana F Clarke, et al.
Lancet (London, England)|January 29, 2019
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 studyMartin R Gaudinski, Emily E Coates, Laura Novik, et al.
Plos Medicine|January 25, 2018
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adultsMartin R Gaudinski, Emily E Coates, Katherine V Houser, et al.
Statistical Communications in Infectious Diseases|December 9, 2017
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy TrialsPeter B Gilbert, Michal Juraska, Allan C deCamp, et al.
Pageof 9